Details: 30 min online online survey Please sign up at the link below to receive an email invite to the survey. Compensation $50 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to …
Metastatic Breast Cancer – What Is It?
View PostRare Patient Voice: Research opportunity for Breast Cancer (metastatic) patients
Details: 30 min online survey Please sign up at the link below to receive an email invite to the survey. Compensation $50 Now accepting Residents from ALL Countries!! * Companies have finally realized the REAL EXPERTS are the Patients and Caregivers! * Better products, services, and treatments, Start with Better Research. They need YOUR input and are willing to pay …
Breast Cancer and Awareness About the Psychological Effects
View PostMetastatic Breast Cancer Awareness
View PostTucatinib Combination Demonstrates Multiple Positive Responses in HER2-Positive Metastatic Breast Cancer
By: Tony Berberabe, MPH From: targetedonc.com Multiple positive responses were observed in an exploratory efficacy analysis evaluating tucatinib (Tukysa) in combination with trastuzumab (Herceptin) and capecitabine in patients with previously treated HER2-positive metastatic breast cancer with brain metastases in the previously reported HER2CLIMB (NCT02614794) trial. Lead author Nancy Lin, MD, and colleagues reported that the combination doubled the intracranial objective …
HER2CLIMB Study Shows Efficacy in HER2 Breast Cancer With Brain Metastases
By: Nancy Lin, MD From: targetedonc.com Nancy U. Lin, MD, discusses the latest findings from the HER2CLIMB study of either tucatinib or placebo, added to trastuzumab and capecitabine, for patients with previously treated HER2-positive metastatic breast cancer who have brain metastases Nancy U. Lin, MD, associate professor of medicine at Harvard Medical School; associate chief of the Division of Breast …
Ask the Expert: 8 Things to Consider About Treatment for MBC
From: healthline.com 1. What treatments are available for postmenopasal women with MBC The metastatic breast cancer (MBC) treatment plan your doctor will recommend depends on whether the tumors have receptors for estrogen or progesterone or elevated levels of human epidermal growth factor receptor 2 (HER2). These are known as a tumor’s biologic subtype. There are various targeted therapies for each …
Immutep’s partner, EOC Pharma, to continue advancing Efti in breast cancer
From: pharmiweb.com Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to inform that EOC Pharma (“EOC”) and Immutep jointly discussed the current AIPAC results and confirmed plans to continue advancing Efti (designated as EOC202 in China) in metastatic breast cancer. The confirmation follows EOC Pharma’s analysis of the recently reported Progression Free Survival (PFS) data, including subgroup …
Trastuzumab Deruxtecan Approved in Japan for HER2+ Metastatic Breast Cancer
By: Jason M. Broderick From: onclive.com The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved trastuzumab deruxtecan (Enhertu) for the treatment of patients with HER2-positive unresectable or recurrent breast cancer who have had prior chemotherapy and are refractory or intolerant to standard treatments. The approval is based on findings from the phase II DESTINY-Breast01 trial, in which the …